Order ready-to-use dPCR assays
*In compliance with the FDA ‘Medical Devices; Laboratory Developed Tests’ final rule, May 6, 2024 and European Union regulation requirements on ‘In-House Assays’ (Regulation (EU) 2017/746 -IVDR- Art. 5(5))
KRAS (Kirsten rat sarcoma viral oncogene homolog) is a gene encoding a GTPase that functions as a molecular switch within the RAS/MAPK signaling pathway. This pathway regulates crucial cellular processes including cell division, differentiation and apoptosis. In colorectal cancer, mutations in the KRAS gene are common and constitute significant oncogenic drivers that lead to the constitutive activation of downstream signaling pathways such as MAPK and PI3K, promoting cellular proliferation and survival independent of external growth signals. The most frequent mutations in KRAS involve codons 12 and 13, which result in a protein that is constitutively active, unable to hydrolyze GTP and perpetually engaged in signaling. This aberrant activity bypasses the normal regulatory mechanisms that would otherwise control cell growth and apoptotic processes, facilitating the development and progression of malignant tumors.
KRAS mutations are associated with resistance to EGFR-targeted therapies such as cetuximab and panitumumab, which are used in the treatment of metastatic colorectal cancer. This resistance arises because the mutated KRAS gene continues to activate the downstream signaling irrespective of EGFR inhibition, rendering these therapies ineffective. The presence of KRAS mutations in a tumor is considered a hallmark of poor prognosis and is integral to therapeutic decision-making in clinical practice, guiding the selection of treatment regimens that do not rely on EGFR blockade.
dPCR LNA Mutation Assays are intended for molecular biology applications. These products are not intended for the diagnosis, prevention, or treatment of a disease.
The QIAcuity is intended for molecular biology applications. This product is not intended for the diagnosis, prevention or treatment of a disease. Therefore, the performance characteristics of the product for clinical use (i.e., diagnostic, prognostic, therapeutic or blood banking) is unknown.
The QIAcuityDx dPCR System is intended for in vitro diagnostic use, using automated multiplex quantification dPCR technology, for the purpose of providing diagnostic information concerning pathological states.
QIAcuity and QIAcuityDx dPCR instruments are sold under license from Bio-Rad Laboratories, Inc. and exclude rights for use with pediatric applications. The QIAcuityDx medical device is currently under development and will be available in 20 countries in H2 2024.